NanoMab is pleased to announce its collaboration in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS).

London, June 5th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, is pleased to announce that it is participating as an Industrial Partner in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS).

The Programme, led by Phil Blower (Professor of Imaging Chemistry at King’s College, London) has been awarded £6 million from the Engineering and Physical Research Council (EPSRC) and is a collaborative partnership between King’s College, Imperial College and Southampton University as well as industrial partners with specific expertise in nuclear medicine. The programme will be formally launched on 8th June.

NanoMab Technologies Ltd has a long-established relationship with King’s College London and is currently working with the School of Biomedical Engineering and Imaging Sciences to initiate a clinical study for a SPECT-based imaging agent which allows the safe acquisition of images of PD-L1 distribution on different tumours in the body before, during and after treatment without biopsy.

Dr Hong Hoi Ting, Nanomab’s founder and Chief Scientific Officer commented, “We are delighted to part of this collaboration with MITHRAS. NanoMab’s long established relationship with King’s College, London, together with our expertise in Radiopharmaceuticals hopefully makes us an ideal industrial partner for the programme.


For more information:

Paul Edwards (CEO, NanoMab). Tel: +44 (0)7771 575374



NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world.

For more information on the MITHRAS programme visit their website: